Sacituzumab for ovarian clear cell carcinoma after immunotherapy
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at a drug called sacituzumab for people with a rare type of ovarian cancer (clear cell carcinoma) that has not responded to immunotherapy. The goal is to see if sacituzumab is safe and effective for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ovarian clear cell carcinoma, a specific type of ovarian cancer.
- Your cancer must have progressed after immunotherapy (such as a PD-1 or PD-L1 checkpoint inhibitor).
- You are expected to be taking or have taken sacituzumab (the study drug) after your immunotherapy stopped working.
- You need to have at least one measurable tumor (a tumor that can be assessed by scans).
- You must be in fairly good health (ECOG performance status score 0-1), with normal kidney and liver function, and an expected survival of at least 1 year.
- You should not have had more than two lines of therapy after progression on immunotherapy, and you must not have used irinotecan or similar antibody-drug conjugates before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests a combination of three drugs — liposomal irinotecan (a type of chemotherapy), sintilimab (an immunotherapy that helps your immune system fight cancer), and anlotinib (a targeted therapy that blocks blood vessels feeding the tumor) — for women with ovarian clear cell carcinoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink or control the cancer better than existing options.
This study tests two investigational drugs, alone or together, for advanced ovarian clear cell cancer that has not responded to usual treatments. The goal is to see if these drugs help shrink or control the cancer.
This trial tests two targeted drugs — sacituzumab tirumotecan (which attacks cancer cells) and bevacizumab (which cuts off blood supply to tumors) — for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination helps shrink or slow the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.